Benchmark Holdings PLC announces an agreement with HypoPet AG for HypoCat

Benchmark Holdings PLC, the international animal health, technical publishing and sustainability science business, announces that its Animal Health division has entered into an agreement with HypoPet AG (“HypoPet”).

With an estimated 10% of the global population suffering from cat allergies, the agreement between HypoPet and Benchmark is designed to open up a new market within the animal health sector with an estimated global value of £250 million. Benchmark’s world-class vaccine manufacturing facilities in Braintree and Edinburgh, combined with its proven vaccine and process development experience puts it in an ideal position to develop and commercialise this innovative new vaccine.

Link to full release from Benchmark